High Grade Gliomas

NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in Patients with High Grade Glioma

Retrieved on: 
Tuesday, March 30, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Brain tumor, Cancer, Oncology, Medical specialties, Health, Neuro-Oncology, Neurology, Glioma, Glioblastoma, Blastoma, High Grade Gliomas, NT-I7, NeoImmuneTech

The investigator-initiated trial is being conducted by neuro-oncologist Jian Li Campian, M.D., Ph.D., of Washington University School of Medicine in St. Louis.

Key Points: 
  • The investigator-initiated trial is being conducted by neuro-oncologist Jian Li Campian, M.D., Ph.D., of Washington University School of Medicine in St. Louis.
  • The primary endpoint of the Phase 2 part of this study is to measure the effect of NT-I7 on absolute lymphocyte count (ALC) compared to placebo control.
  • High grade gliomas (HGGs) indicate collectively the presence of grade 3 or 4 malignant tumors, which tend to grow rapidly and spread faster than tumors of a lower grade, in brain tissue.
  • Recent data suggest that the inferior survival rate in patients with glioblastoma is associated with very low T cell counts.